IRIS
PENDE, ALDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 14.995
AS - Asia 44
SA - Sud America 4
Totale 15.043
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 14.995
CN - Cina 36
SG - Singapore 5
BR - Brasile 4
VN - Vietnam 2
ID - Indonesia 1
Totale 15.043
Salva come PNG Salva come JPEG
Città #
Genova 9.560
Genoa 3.210
Rapallo 1.218
Vado Ligure 955
Bordighera 51
Beijing 12
Singapore 5
Arês 1
Hanoi 1
Maravilhas 1
Medan 1
Phú Thọ 1
Recife 1
São Simão 1
Totale 15.018
Salva come PNG Salva come JPEG
Nome #
Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. 205
Anti-apolipoprotein A-1 auto-antibodies as active modulators of atherothrombosis 201
Lipoproteins, stroke and statins. 199
Angiotensin II receptor antagonists in acute coronary syndromes. 181
Characterization of the binding of the RNA-binding protein AUF1 to the human AT1 receptor mRNA. 178
Anti-Apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability 177
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 177
Characteristics of current heart failure patients admitted to internal medicine vs. cardiology hospital units: the VASCO study 168
Treatment with recombinant tissue plasminogen activator (r-TPA) induces neutrophil degranulation in vitro via defined pathways. 167
Baseline hs-CRP predicts hypertension remission in metabolic syndrome 166
Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. 163
The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. 161
Clorhexidine prevents hypoclorous acid-induced inactivation of alpha1-antitrypsin. 158
Role of Neutrophils in Atherogenesis: an Update 157
Inflammation in the pathophysiology of essential hypertension. 154
Prevalence of erectile dysfunction in a cohort of Italian hypertensive subjects 154
Serum adiponectin levels predict acute coronary syndrome (ACS) in patients with severe carotid stenosis 154
Treatment with Angiotensin-(1-7) reduces inflammation in carotid atherosclerotic plaques. 153
Plasma dopamine response to sympathetic activation in man: a biphasic pattern. 152
Anti-inflammatory approaches to reduce acute cardiovascular events: not only benefits. 151
Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis 151
Circadian variations of autologous mixed lymphocyte reactions and endogenous cortisol. 151
Blunted response of serum aldosterone to metoclopramide in the male elderly 150
Clinical predictors of late SARS-CoV-2 positivity in Italian internal medicine wards 146
HPLC with electrochemical detection of catecholamines in human plasma, a mini-review. 145
Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. 144
Carotid atherosclerotic plaque stenosis: the stabilizing role of statins. 143
Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia 143
Serum PCSK9 levels predict the occurrence of acute coronary syndromes in patients with severe carotid artery stenosis 143
Evidence for interactions between HLA system class I and beta-adrenergic receptors in human mononuclear leukocytes. 141
Anti-ApoA-1 auto-antibodies increase cardiovascular vulnerability. 139
Serum levels of osteopontin predict major adverse cardiovascular events in patients with severe carotid artery stenosis 139
Morphine-induced TSH release in normal and hypothyroid subjects. 135
Yohimbine effects on blood pressure and plasma catecholamines in human hypertension 135
Carotid ultrasonography in the assessment of cardiovascular risk 135
Vitamin D receptor is expressed within human carotid plaques and correlates with pro-inflammatory M1 macrophages 135
Agonist-mediated destabilization of human b1-adrenergic receptor mRNA: role of the 3’ untranslated region. 133
Update on the evidence of statin treatment to reduce plaque vulnerability. 133
Free and sulfoconjugated catecholamines in normotensive uremic patients: effects of hemodialysis. 132
Inflammation Is a Key Pathophysiological Feature of Metabolic Syndrome. 132
Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. 131
Anti-apoliprotein A-1 autoantibodies are active mediators of atherosclerotic plaque vulnerability. 131
Cardiovascular prevention: Can we do any better? 129
Correlation between Progetto Cuore risk score and early cardiovascular damage in never treated subjects 128
Serum lipoprotein (a) predicts acute coronary syndromes in patients with severe carotid stenosis 128
Classical and new renin-angiotensin signalling in atherosclerosis. 127
The renin-angiotensin system modulates inflammatory processes in atherosclerosis: evidence from basic research and clinical studies. 126
Platelet-to-lymphocyte ratio at the time of carotid endarterectomy is associated with acute coronary syndrome occurrence 125
Inflammatory cardiovascular risk biomarkers: update on novelties and limitations. 125
Resistin exerts a beneficial role in atherosclerotic plaque inflammation by inhibiting neutrophil migration 124
Purification and characterization of b-adrenergic receptor mRNA-binding proteins. 122
Editorial: is ischemic stroke an inflammatory disease? 121
Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk 120
Neutrophil migration towards C5a and CXCL8 is abrogated by non-steroidal anti-inflammatory drugs (NSAIDs) via the inhibition of different pathways. 119
Recombinant tissue plasminogen activator induces neutrophil degranulation activating PI3K/Akt- and ERK1/2-mediated pathways. 119
Adiponectin/leptin ratio predicts the remission of metabolic syndrome: A pilot study 116
Prognostic impact of diabetes and prediabetes on survival outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial 115
Epinine kinetics and plasma catecholamine changes following oral administration of the prodrug ibopamine in patients with chronic heart failure. 114
Simultaneous measurement of plasma catecholamine (norepinephrine, epinephrine and dopamine) and free N-methyl dopamine (epinine) levels, by HPLC with electrochemical detection. 114
Adrenergic receptors: relevance to myocardial signal transduction in heart failure. 113
Effects of the H2-receptor antagonist ranitidine on anterior pituitary hormone secretion in man. 112
Evaluation of pituitary-thyroid function and prolactin secretion in healthy aged subjects. 111
Renin-Angiotensin antagonists: therapeutic effects beyond blood pressure control? 107
Effects of blood pressure control in cardiovascular prevention 107
Measurement of conjugated catecholamines in human plasma. A low cost HPLC ECD method. 105
Regulation of the mRNA-binding protein AUF1 by activation of the b-adrenergic receptor signal transduction pathway. 105
Identification and intracellular localization of RNA-binding proteins involved in the modulation of the hAT1 receptor mRNA stability. 105
Regular Wine Consumption in Chronic Heart Failure: Impact on Outcomes, Quality of Life, and Circulating Biomarkers 104
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial 104
Preliminary characterization of a transgenic mouse overexpressing the human b1-adrenergic receptor. 103
Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial 103
Myocardial-directed overexpression of the human b1-adrenergic receptor in transgenic mice. 102
Differential binding of p37AUF1 to beta-adrenergic receptor mRNAs. 102
Effect of clonidine on gonadotropin secretion in normal men. 100
Correlation between intrinsic mRNA stability and the affinity of AUF1 (hnRNPD) and HuR for A+U-rich mRNAs. 100
Effects of rosuvastatin on atrial fibrillation occurrence: Ancillary results of the GISSI-HF trial 100
Intraindividual variation of beta2-adrenergic receptors on mononuclear leukocytes and their relationships with endogenous plasma catecholamines in man. 99
Evidence for adrenergic mediation of the effect of morphine on LH secretion in normal men. 99
Norepinephrine-induced plasma dopamine decrease in man: pharmacological evidence of the involvement of alpha2-adrenoceptors 99
Characterization of RNA-binding proteins possibly involved in modulating human AT 1 receptor mRNA stability. 99
Alpha-adrenergic control of TSH secretion in man. 98
Syndrome of inappropriate antidiuretic hormone secretion and Ibuprofen, a rare association to be considered: role of tolvaptan. 97
Reversed-phase HPLC separation of plasma norepinephrine, epinephrine, and dopamine with three-electrode coulimetric detection. 97
Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation 96
Regulation of p37AUF1, an mRNA binding protein, in human ventricular myocardium. 95
Evaluation of the effects induced by four opiate drugs, with different affinities to opioid receptor subtypes, on anterior pituitary LH, TSH, PRL and GH secretion and on cortisol secretion in normal men. 95
Is the carotid plaque rupture a pivotal event in stroke pathogenesis? Update on the role of the intraplaque inflammatory processes 95
Ankle-Brachial Index and cardiovascular events in atrial fibrillation: The ARAPACIS study 95
The 3’ untranslated region of the human beta1-adrenergic receptor is necessary but not sufficient for agonist-mediated destabilization. 94
Medication prescription and adherence disparities in non valvular atrial fibrillation patients: an Italian portrait from the ARAPACIS study 94
Evaluation of some aspects of growth hormone regulation in aging. 93
Effects of opioid substances on cAMP response to the beta-adrenergic agonist isoproterenol in human mononuclear leukocytes 93
An inflammatory approach in the therapeutic choices for the prevention of atherosclerotic events 92
Neuroendocrine effects of Interferon alpha 2-a in healthy human subjects. 91
ß-adrenergic receptor mediated regulation of p37AUF1, an mRNA binding protein, in DDT1-MF2 cells. 90
Receptor activator of NF-kappa B ligand (RANKL) increases neutrophilic degranulation and potentially associated cardiovascular risk. 90
The cardiokine secreted Frizzled-related protein 3, a modulator of Wnt signalling, in clinical and experimental heart failure 90
Treatment with oxaprozin reduces neutrophil migration in response to C5a and CXCL8 via the inhibition of the PI3K/Akt pathway. 89
Troponin elevation does not always mean cardiac ischemia. 89
Effects of Interferon alpha 2-a on catecholamines and lymphocyte beta2-adrenoceptors in healthy humans. 88
Totale 12.555
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.261
article - articoli 44.945
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.316
Totale 94.522
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021795 0 0 0 118 63 73 46 93 112 138 58 94
2021/20221.579 61 97 75 223 70 149 69 368 72 149 57 189
2022/20231.469 144 75 24 162 232 294 2 102 270 4 130 30
2023/2024749 25 128 23 76 66 95 56 81 47 14 36 102
2024/20252.247 61 172 70 134 357 228 200 326 77 114 199 309
2025/20261.043 437 132 252 222 0 0 0 0 0 0 0 0
Totale 15.326